The French pharma group has just been granted a fast-track designation from the FDA for a preclinical-stage mRNA-based vaccine candidate that is due to start a phase 1/2 trial in the coming days ...

The FDA has given a fast-track designation to a gonorrhoea vaccine in development at GSK that could help turn the tide of the sexually-transmitted infection, which is on the rise around the world.